Ad hoc announcement pursuant to Art. 53 LR Ypsomed sells its diabetes business and grows by over 35% Burgdorf, 21.05.2025, 07:00 a.m. – Ypsomed (SIX: YPSN) continues its growth trajectory and achieved consolidated sales of CHF 748.9 million in the financial year 2024/25 (prior year: CHF 548.5 million). Adjusted for the divested pen needle and blood glucose monitoring business and other one-off effects, this represents 37.9% growth or CHF 193.0 million, in line with guidance. Reported operating profit (EBIT) was CHF 112.9 million (prior year: CHF 86.2 million). Adjusted for one-off effects, EBIT in line with guidance reached CHF 140.5 million, representing 42.5% growth. Net profit increased by CHF 9.1 million to CHF 87.5 million (prior year: CHF 78.4 million). Ypsomed has signed an agreement to sell its Diabetes Care business and will now concentrate on expanding its leading position in the Delivery Systems business. 
Other key highlights: - Autoinjectors commercial sales growth of 50%.
- mylife YpsoPump system commercial sales increase of 81%.
- Inauguration of the fourth production hall and laying of the foundation stone for a second plant in Schwerin, Germany.
- Creation of 364 new jobs, 180 of which are in Switzerland.
"We are focusing on the very large subcutaneous self-injection market potential. Our fundamental growth drivers – the increasing prevalence of self-medication, the growth of biologics and biosimilars – remain unchanged. Demand for injection systems for chronic conditions is only slightly affected by macroeconomic cycles or political developments. With our automated and scalable processes, we are therefore ideally positioned to successfully participate in our growing addressable markets," comments Simon Michel, CEO, on Ypsomed prospects.
Outlook
Ypsomed expects revenue growth of around 20% and an EBIT between CHF 190 and 210 million in the continued Delivery Systems business for the financial year 2025/26. With the sale of Diabetes Care on 21 April 2025 and the exit from the insulin pump business, Ypsomed is also discontinuing development services for the patch pump. It was also decided to classify the Ypsotec division as a discontinuing operation. The reported sales and EBIT therefore include significant effects from discontinued and discontinuing operations that are no longer part of Ypsomed's core injection systems business.
Ypsomed Delivery Systems grows by 30%
The Ypsomed Delivery Systems segment grew by 30.4% or CHF 117.1 million in the year under review. Segment sales for the reporting period amounted to CHF 502.3 million (previous year: CHF 385.2 million). - The strong increase of 49.8% in commercial autoinjector deliveries was especially welcomed.
- The strong growth of 46.2% in the project business for pens and autoinjectors is also encouraging. In the period under review, we generated project sales of CHF 98.5 million (previous year: CHF 67.4 million).
- The acquisition of new projects continued to be successful with 36 new projects secured.
"In addition to the tremendous growth around the well-known GLP-1-based drugs for the treatment of diabetes and obesity, we see great growth potential in a large number of different indications. We have the most comprehensive product portfolio on the market and our flexible production facilities enable us to work with small biotech companies as well as large pharmaceutical groups and the growing number of biosimilar suppliers," says Ulrike Bauer, Chief Business Officer Delivery Systems, pleased with the positive development. Growth of 81% with mylife YpsoPump
The Ypsomed Diabetes Care segment generated sales of CHF 236.9 million in the financial year 2024/25 (previous year: CHF 151.0 million). - Of which, CHF 28.3 million (prior year: CHF 39.4 million) was attributable to the pen needles and blood glucose monitoring devices business sold at the end of July 2024.
- This segment also includes development services for the patch pump on behalf of TecMed AG. This contributed a total of CHF 29.5 million to sales, of which CHF 18.5 million came from the agreed exit and the associated expected revenue.
- The insulin pump business with the mylife YpsoPump achieved commercial sales of CHF 175.3 million (prior year: CHF 97.0 million), which corresponds to 80.8% growth.
Sales growth of the mylife YpsoPump was driven by the following factors: - mylife Loop, the solution for automated insulin dosing with a self-learning algorithm accessible via the smartphone reached around 70 000 users by the end of March 2025.
- The growth came mainly from Germany, France, the UK, Australia and Spain.
"With mylife Loop, our innovative solution for automated insulin delivery consisting of the mylife YpsoPump and the mylife CamAPS FX app, we have shown that we can achieve sustainable growth in insulin pump therapy. Alongside a highly motivated team, I look forward to unlocking the full potential for people with diabetes," welcomes Sébastien Delarive, current Chief Business Officer Diabetes Care at Ypsomed and designated CEO of TecMed AG in the new organisational set up. Good return on capital employed for continued business
The reported EBIT reached CHF 112.9 million (previous year CHF 86.2 million) and EBIT from continuing operations, namely injection system business amounted to CHF 167.0 million. This corresponds to an EBIT margin of 33.3% and a ROCE (return on capital employed) of approximately 20%. In the reporting period, Ypsomed achieved a net profit of CHF 87.5 million (previous year: CHF 78.4 million). Earnings per share amounted to CHF 6.41 (previous year: CHF 5.74). Ypsomed 2030 investment program
As part of the Ypsomed 2030 global investment program, the company is expanding production at the existing sites in Switzerland and Germany as well as building new production facilities in China and North America. The fourth production hall in Schwerin, Germany, was inaugurated in October 2024. In January 2025, construction work also began on a second plant in Schwerin. Over the next two years, the production area in Germany will be expanded by a total of 37 000 square meters. The new production hall in Changzhou, China, has been completed and the first production machinery and equipment have been installed. The site will officially open in June 2025. At the same time, the North America site selection process is well underway. The diversification of production sites and proximity to our most important end markets increase our supply chain resilience for customers. Sale of Ypsotec initiated
The Board of Directors has decided to initiate the sale of Ypsotec. Ypsotec produces complex precision and milled parts for the medical technology, semiconductor and aerospace industries. There are no longer any relevant synergies with the continuing business. This is a step forward in supporting Ypsomed to focus on its core business and become a specialist in injection systems. Further investments to support future growth
Driven by growth investments, Cash Flow from investing activities reached a new high at CHF -267.3 million, a significant increase compared to the previous year's level (prior year: CHF -195.1 million). Of this, CHF -205.6 million (prior year: CHF -116.4 million) was invested in property, plant and equipment, for the capacity expansion for autoinjectors and pens at the Swiss sites, in Schwerin, Germany, and in Changzhou, China. CHF -71.5 million (prior year: CHF -78.9 million) was invested in intangible assets to further develop the pen and autoinjector platforms, the mylife YpsoPump, and digital solutions in our digital health business. 10% increase in dividends
The Board of Directors will propose at the Annual General Meeting to pay out a dividend of CHF 2.20 per share (previous year: CHF 2.00) for the financial year 2024/25, half from capital reserves and half from retained earnings. Media and Analyst Conference
Ypsomed will present its results for the financial year 2024/25 at 11:00 a.m. CEST on 21 May 2025 at the Park Hyatt Hotel in Zurich, Switzerland. The conference will take place in English, with participation available on-site or through a live webcast. Please register here to attend: Media and Analyst Conference for the 2024/25 full-year results. Capital Market Day
Ypsomed is holding a Capital Market Day on Monday, 29 September 2025, at its manufacturing site in Schwerin, Germany. Analysts, investors and media representatives will receive in-depth information on strategy, innovations and business development. The Annual General Meeting of Ypsomed Holding AG will take place on 02 July 2025 in Burgdorf. Detailed reporting and further information can be found in the 2024/25 Annual Report, available at www.ypsomed.ch/reports. | 